Asterias Biotherapeutics Gets Additional Clinical Site for Study

- August 23rd, 2017

Asterias Biotherapeutics announced the addition of the Washington University School of Medicine in St. Louis as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1.

Asterias Biotherapeutics (NYSEMKT:AST) announced the addition of the Washington University School of Medicine in St. Louis as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1.
As quoted in the press release:

Washington University and its partner Barnes-Jewish Hospital have one of the largest clinical spine care practices in the United States. W. Zachary Ray, MD, Associate Professor of Neurological and Orthopedic Surgery at Washington University School of Medicine, will be the site’s principal investigator. Patients enrolled in the trial will receive the AST-OPC1 treatment during surgery at Barnes-Jewish.
“Given the study’s encouraging early results, we look forward to evaluating whether AST-OPC1 can advance treatment options for patients with severe cervical spinal cord injuries. This investigational therapy is an important contribution to our comprehensive program to treat spinal cord injuries here at Washington University and Barnes-Jewish,” said Dr. Ray.

Barnes-Jewish Hospital’s Trauma Center was the first in Missouri to receive the American College of Surgeons (ACS) Level I verification, which is the highest national recognition possible from ACS.

Click here to read the full press release.

Leave a Reply

Your email address will not be published. Required fields are marked *